A Novel Paclitaxel Eluting Bioresorbable Coronary Stent 3D Printed from a Tougher and Faster Degradation Poly(L-Lactide-Co-Caprolactone) Co-Polymer

Wei Liu,Qingqing Li,Ge Song,Zhiqi Lin,Xiaofei Gong,Hanqing Feng,Hugh Q. Zhao,Yujie Zhou,Zhongyong Fan,Qing Liu
DOI: https://doi.org/10.2139/ssrn.4520883
2023-01-01
Abstract:Bioresorbable stents (BRS) have emerged as a groundbreaking development in the field of percutaneous coronary intervention (PCI) as they address the long-standing concerns of metallic stents. Nevertheless, the observed higher thrombosis rates in Absorb BVS were attributed to the thicker strut thickness and structural dismantling of partially endothelialized stents. The suggested measures to overcome these limitations include reducing strut thickness, modifying the structural design to maintain radial strength with thinner struts, using round cross-section struts for easier embedding into vessel walls, and exploring new materials that are tougher and degrade faster than poly(L-lactide) (PLLA). In this paper, 3D printed poly (L-lactide-co-ɛ-caprolactone) (PLCL 95/5) coronary stents with paclitaxel elution were studied in vitro and in vivo. The novelty of this study involved the fabrication of totally bioresorbable 3D printed PLCL polymer stents using the four-axis 3D printing system. The paclitaxel eluting PLCL stents had thinner struts, a faster degradation profile, and satisfactory biocompatibility. With a paclitaxel dose of 0.57μg/mm2, the drug eluting stents showed very low degree of stenosis within 6 months of implantation. Overall, the results showed a very promising candidate for next generation bioresorbable coronary stents.
What problem does this paper attempt to address?